Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK2292767 is a potent and selective PI3Kδ inhibitor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | 4-6weeks | $ 132.00 | |
10 mg | 4-6weeks | $ 210.00 | |
25 mg | 4-6weeks | $ 462.00 | |
50 mg | 4-6weeks | $ 784.00 | |
1 mL * 10 mM (in DMSO) | 4-6weeks | $ 210.00 |
Description | GSK2292767 is a potent and selective PI3Kδ inhibitor. |
In vitro | BI-847325 shows growth-inhibitory effects on BRAF-mutant and vemurafenib-resistant melanoma cells with IC50 ranging from 0.3 nM to 2 μM, and prevents colony formation in six BRAF-mutant melanoma cell lines. BI-847325 also induces apoptosis by reducing Mcl-1 expression. [1] |
In vivo | GSK2292767 is highly selective for PI3Kδ over the closely related isoforms and is active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation[1]. |
Molecular Weight | 512.58 |
Formula | C24H28N6O5S |
CAS No. | 1254036-66-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 93 mg/mL (181.4 mM)
Ethanol: <1 mg/mL
H2O: <1 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK2292767 1254036-66-2 PI3K/Akt/mTOR signaling PI3K GSK 2292767 Phosphoinositide 3-kinase Inhibitor disease PI3Kδ respiratory inhibit GSK-2292767 inhibitor